Harmony Biosciences Holdings, Inc.

NasdaqGM HRMY

Harmony Biosciences Holdings, Inc. Price to Book Ratio (P/B) on January 14, 2025: 3.92

Harmony Biosciences Holdings, Inc. Price to Book Ratio (P/B) is 3.92 on January 14, 2025, a 0.58% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Harmony Biosciences Holdings, Inc. 52-week high Price to Book Ratio (P/B) is 4.53 on September 26, 2024, which is 15.38% above the current Price to Book Ratio (P/B).
Harmony Biosciences Holdings, Inc. 52-week low Price to Book Ratio (P/B) is 3.37 on June 20, 2024, which is -14.22% below the current Price to Book Ratio (P/B).
Harmony Biosciences Holdings, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 3.77.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqGM: HRMY

Harmony Biosciences Holdings, Inc.

CEO	Dr. Jeffrey M. Dayno M.D.
IPO Date	Aug. 19, 2020
Location	United States
Headquarters	630 West Germantown Pike
Employees	246
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Key trends

Past 5 years